NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Pat DeMartino, MD; Douglas Carr, MD; Russ Huffman, PMHNP Cat Livingston, MD; Caryn Mickelson, PharmD; Robin Moody, MPH; Eriko Onishi, MD; Bill Origer, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH; Deborah Weston, JD; Amanda Parish

Audience: Mark Kantor, AllCare CCO; Carole Eisner, Novartis; Erin Nowak, AbbVie; Kevin Gallagher, Fennec Pharmaceuticals; Zachariah Thomas, Axsome*; YJ Shukla, EOCCO; Brain Howell, Novartis; Gary Paretneau, Dexcom; Chris Ferrin, IHN; Brandie Feger, Advanced Health CCO; Bill McDougal, Biogen; Lisa Ashton, J&J; Lori McDermott, Viking HCS; Michele Sabados, Alkermes; Mark Wolber, Sunovion; Jeremy Strand, Alexion; Shauna Wick; Dennis Murphy, Axsome; Paul Thompson, Alkermes*; Nic Vandersloot, Confederated Tribes of the Siletz; Jamie Tobitt, Apellis*; Lynda Finch, Biogen*; Donald Nopper, Apellis; Georgette Dzwilewsk, Indivior; Matt Worthy, OHSU; Mariah Shoffner, APPE Student CIT; Tiffany Jones, PacificSource; Bill Eicholzer, Alexion; Susan Lakey Kevo, Janssen; Uche Mordi, BMS; Joni Fusick; Erika Finanger; OHSU*; Tiina Andrews, UHA; Jared McPhail, Argenx*; Jim Slater, CareOregon; Marc Rueckert, Argenx; Matt Metcalf, CSL Vifor; Michael Foster, BMS; Norm Navarro, Providence Health Plan; Rick Frees, Vertex Pharmaceutical; Saghi Maleki, Takeda; Nirmal Ghuman, Janssen*

(*) Provided verbal testimony
I. CALL TO ORDER

A. Roll Call & Introductions
   - Called to order at approx. 1:05 p.m., introductions by Committee and staff
B. Conflict of Interest Declaration – no new conflicts of interest were declared
C. Election of Chair and Vice-Chair
   Dr. Ramirez volunteered to serve as Chair and Dr. DeMartino as Vice-Chair
   ACTION: Motion to approve, 2nd, all in favor
D. Approval of Agenda and December 2022 Minutes presented by Roger Citron
   ACTION: Motion to approve, 2nd, all in favor with two abstentions
E. Department Update provided by Andrew Gibler, PharmD
F. Legislative Update provided by Dee Weston, JD

II. CONSENT AGENDA TOPICS

A. Preferred Drug List (PDL) Old Business: Inhaled Anticholinergics
   - No PDL changes recommended based on the clinical evidence
   - Evaluate costs in executive session
B. P&T Evidence Methods
C. P&T Operating Procedures
D. Oncology Prior Authorization (PA) Updates
   Recommendation:
   - Add: Krazati® (adagrasib); Rezlidhia™ (olutasidenib); and Elahere™ (mirvetuximab soravtansine-gynx) to Table 1 in the Oncology Agents prior authorization (PA) criteria
E. Orphan Drug Policy Updates
   Recommendation:
   - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Xenpozyme™ (oplipudase alfa-rpcp) and Cuvrior™ (trientine tetrahydrochloride) based on FDA-approved labeling
   ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

A. Quarterly Utilization Report: Roger Citron, RPh
B. ProDUR Report: Lan Starkweather, PharmD
C. RetroDUR Report: Dave Engen, PharmD
D. Oregon State Drug Review: Kathy Sentena, PharmD
   - Antimicrobial Stewardship
   - An Update in Lipid Lowering Therapies
   - COVID-19 Vaccine Bivalent Boosters
IV. PREFERRED DRUG LIST NEW BUSINESS

A. GnRH Antagonists PA Update: Deanna Moretz, PharmD
Recommendations:
- Revise PA criteria for relugolix, estradiol, and norethindrone combination therapy to include management of moderate to severe pain associated with endometriosis in premenopausal women
ACTION: The Committee amended the proposed criteria to require a trial of at least three months’ duration of first-line therapy in question #13
Motion to approve, 2nd, all in favor

B. Antidepressant Class Update: Kathy Sentena, PharmD; Andrew Gibler, PharmD
Recommendations:
- No PDL changes recommended based on review of recently published evidence
- Update PA criteria for tricyclic antidepressants, esketamine and brexanolone as presented
- Evaluate costs in executive session
ACTION: Motion to approve, 2nd, all in favor

C. Spinal Muscular Atrophy DERP Report: Deanna Moretz, PharmD
Recommendations:
- No PDL changes recommended based on review of recently published evidence
- Combine PA criteria for all 3 treatments into one with updates to clarify duration of therapy and FDA-approved age ranges
- Include pregnancy risk assessment for risdiplam
ACTION: The Committee amended the proposed criteria to remove the requirement that improvement be documented within one month of the renewal request
Motion to approve, 2nd, all in favor

D. Medications for Substance Use Disorders, Opioid & Alcohol:
Deanna Moretz, PharmD; Sarah Servid, PharmD
Recommendations:
- No PDL changes recommended based on review of recently published evidence
- Retire the PA criteria for lofexidine as there has been no utilization in the past year
- Update PA criteria to limit use of all long-acting opioids to patients who have inadequate pain relief with short-acting opioids
ACTION: The Committee recommended maintaining the safety edits present in the current long-acting PA criteria after amending to replace “pain contract” with “pain agreement” and allow up to 12-month renewal approvals for members established on
treatment with no risk factors. The Committee also recommended requiring a taper plan for members new to the OHP for ongoing opioid treatment when their diagnosis is unfunded or if they have certain risk factors.

Motion to approve, 2nd, all in favor

E. Biologics for Rare Conditions Class Update: Deanna Moretz, PharmD

Recommendations:
- No PDL changes recommended based on review of recently published evidence
- Revise Ravulizumab PA criteria to include use and dosing guidance in adults with generalized MG who are anti-AChR antibody positive and add SC dosing recommendations for adults with PNH and aHUS
- Update PA criteria to support case by case review for members less than 21 years old with unfunded diagnosis, to evaluate whether medically appropriate and necessary

V. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Pat DeMartino, MD; Douglas Carr, MD; Russ Huffman, PMHNP; Cat Livingston, MD; Caryn Mickelson, PharmD; Robin Moody, MPH; Eriko Onishi, MD; Bill Origer, MD

Staff Present: Sarah Servid, PharmD; Deanna Moretz, PharmD; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Andrew Gibler, PharmD

VI. RECONVENE for PUBLIC RECOMMENDATIONS

A. Inhaled Anticholinergics
   Recommendation: Maintain Combivent Respimat® as preferred on the PDL
   ACTION: Motion to approve, 2nd, all in favor

B. Antidepressant Class Update
   Recommendations: Make nefazodone preferred and make protriptyline & trimipramine voluntary non-preferred
   ACTION: Motion to approve, 2nd, all in favor

C. Biologics for Rare Conditions Class Update
   Recommendations: Make no changes to the PDL
   ACTION: Motion to approve, 2nd, all in favor
VIII. ADJOURN